Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. UBER shares hit an all-time high on Thursday above the Feb. 2021 high. He remains long on the stock and still loves it.

Goldman Sachs analyst Eric Sheridan maintained Uber Technologies with a Buy and raised the price target from $59 to $78.

Bryn Talkington of Requisite Capital Management picked Sprott Uranium Miners ETF URNM, saying that uranium had a strong year in 2023 and it’s going to be another strong year.

Don’t forget to check out our premarket coverage here

Brenda Vingiello of Sand Hill Global Advisors named Abbott Laboratories ABT as her final trade.

On Thursday, RBC Capital analyst Shagun Singh maintained Abbott Laboratories with an Outperform rating and raised the price target from $119 to $128.

Jim Lebenthal of Cerity Partners said Vertex Pharmaceuticals Incorporated VRTX reached an all-time high on Thursday. This is a "very good" pharmaceutical biotech play, he added.

Vertex recently announced the approval of first CRISPR/Cas9 gene-edited therapy, CASGEVY, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia in Kingdom of Saudi Arabia.

Price Action

• Uber shares gained 1.7% to close at $63.47
• Sprott Uranium Miners ETF fell 3% on Thursday
• Abbott Laboratories fell 0.3% to $113.50
• Vertex Pharmaceuticals gained by 1.5% to $430.08 during Thursday’s session.

Check This Out: How To Earn $500 A Month From JPMorgan Stock Ahead Of Q4 Earnings Report